Fredun Pharmaceuticals (539730) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 total income reached INR 160.92 crore, up 57% year-on-year, with EBITDA at INR 26.34 crore, growing 99% year-on-year and margins improving to 16% (up 384 bps).

• Net profit for Q3 was INR 10.48 crore, up 96% year-on-year, with net profit margin at 7%. EPS for the quarter was INR 22.19.

• For the nine-month period, total income was INR 426 crore (up 48% YoY), EBITDA INR 65.66 crore (up 74% YoY), and net profit INR 26.98 crore (up 96% YoY).

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with review by statutory auditors and Audit Committee.

• Financial statements prepared in accordance with Ind AS and SEBI regulations, with unmodified review reports from auditors.

Financial highlights

• Q3 EBITDA margin improved to 16%, up 384 bps YoY; nine-month EBITDA margin at 15%, up 237 bps.

• Net profit margin for Q3 at 7%, and for nine months at 6%.

• EPS for nine months stood at INR 57.13 standalone and INR 56.50 consolidated.

• Standalone revenue for the quarter ended 31 December 2025 was ₹16,092.33 lakhs, up from ₹10,269.67 lakhs in the same quarter last year.

• Standalone net profit for the quarter was ₹1,047.81 lakhs, compared to ₹533.26 lakhs year-over-year.

Outlook and guidance

• No immediate need for additional funds in the next 12–18 months; future funding may be considered after 18–30 months if required for new divisions.

• Guidance remains conservative to account for market uncertainties, but management is confident of overachieving current targets.

• By FY29–30, 51% of revenue is targeted to come from New Age business, with vintage business expected to grow 12–18% YoY and New Age business 20–25% YoY.